Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Zhou, Fei ^a   Li, Ning ^a   Jiang, Weihua ^a   Hua, Zhaolai ^b   Xia, Lin ^b   Wei, Qingyi ^c   Wang, Liwei ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b Yangzhong People's Hospital   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

FISH; Gastric cancer; HER 2 neu; IHC; Prognosis

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CELL DIFFERENTIATION; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH CANCER; TISSUE MICROARRAY;

ADULT; AGED; CHINA; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84871122460     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-274     Document Type: Article

References (30)

1. Chen WQ. Estimation of cancer incidence and mortality in China in 2004-2005. Zhonghua Zhong Liu Za Zhi 2009, 31:664-668.
2. Qin SQ, GX. The status quo and new progress in the chemotherapy of the advanced gastric cancer. Chin Clin Oncol 2006, 11:641-652.
3. Meza-Junco J, Sawyer MB. Metastatic gastric cancer - focus on targeted therapies. Biologics 2012, 6:137-146. 3395896, 22807624.
4. Bang YJ, van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, . ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X, 20728210, ToGA Trial Investigators.
5. Shitara K, Yatabe Y, Matsuo K, Sugano M, Kondo C, Takahari D, Ura T, Tajika M, Ito S, Muro K. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer 2012, . [Epub ahead of print].
6. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981, 290:261-264. 10.1038/290261a0, 7207618.
7. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999, 26:51-59.
8. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 1993, 71:3942-3946. 10.1002/1097-0142(19930615)71:12<3942::AID-CNCR2820711224>3.0.CO;2-3, 8099528.
9. Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001, 14:556-562. 10.1038/modpathol.3880350, 11406656.
10. Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 1997, 28:827-833. 10.1016/S0046-8177(97)90157-X, 9224752.
11. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001, 10:139-152. 10.1097/00019606-200109000-00001, 11552716.
12. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273-278. 10.1093/annonc/mdi064, 15668283.
13. Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rego S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009, 100:487-493. 10.1038/sj.bjc.6604885, 2658544, 19156142.
14. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19:1523-1529. 10.1093/annonc/mdn169, 18441328.
15. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Il Sohn C, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006, 51:1371-1379. 10.1007/s10620-005-9057-1, 16868827.
16. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012, 18:5992-6000. 10.1158/1078-0432.CCR-12-1318, 22977193.
17. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805. 10.1111/j.1365-2559.2008.03028.x, 18422971.
18. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007, 38:1386-1393. 10.1016/j.humpath.2007.02.005, 17555797.
19. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001, 19:2714-2721.
20. Bae CD, Juhnn YS, Park JB. Post-transcriptional control of c-erb B-2 overexpression in stomach cancer cells. Exp Mol Med 2001, 33:15-19. 10.1038/emm.2001.3, 11322480.
21. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011, 18:2833-2840. 10.1245/s10434-011-1695-2, 21468783.
22. Begnami MDFE, Fregnani JH, Nonogaki S, Montagnini AL, Da Costa WL, Soares FA. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011, 29:3030-3036. 10.1200/JCO.2010.33.6313, 21709195.
23. Liu W, Zhong S, Chen J, Yu Y. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol 2012, 46:e31-e37. 10.1097/MCG.0b013e31823457ea, 22064554.
24. Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, Hwang TL, Jan YY, Yeh TS. Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist 2011, 16:1706-1713. 10.1634/theoncologist.2011-0199, 3248769, 22143936.
25. Chung H, Bang YJ, Xu JM, Lordick F, Sawaki A, Lipatov O, Lehle M, Pickl M, Rueschoff J, van Cutsem E. 6511 Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing. European Journal of Cancer Supplements 2009, 7:364.
26. Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, Funke I. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993, 53:1690-1695.
27. Machado J, Carneiro F, Sobrinho-Simoes M. E-cadherin mutations in gastric carcinoma. J Pathol 2000, 191:466-468. 10.1002/1096-9896(200008)191:4<466::AID-PATH626>3.0.CO;2-Q, 10918224.
28. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki I, Endou Y, Tanaka M, Sasaki T. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991, 67:2914-2918. 10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G, 1673870.
29. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993, 72:2083-2088. 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1, 8397058.
30. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brummendorf TH, Bokemeyer C, Izbicki JR, Sauter G. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009, 40:769-777. 10.1016/j.humpath.2008.11.014, 19269014.